Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Rebernick

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Cancer Discovery|October 7, 2025
Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancerNofar Gumpert, Shira Sagie, Claudia Arnedo-Pac, et al.
The Journal of Clinical Investigation|June 2, 2025
PROX1 is an early driver of lineage plasticity in prostate cancerZhi Duan, Mingchen Shi, Anbarasu Kumaraswamy, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Cancer Discovery|October 7, 2025
Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancerNofar Gumpert, Shira Sagie, Claudia Arnedo-Pac, et al.
The Journal of Clinical Investigation|June 2, 2025
PROX1 is an early driver of lineage plasticity in prostate cancerZhi Duan, Mingchen Shi, Anbarasu Kumaraswamy, et al.
Pageof 2